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submitted to neoadjuvant chemotherapy
with pathological non-complete response
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Abstract
Background: Breast cancer with pathological non-complete response (non-pCR) after neoadjuvant chemotherapy
(NAC) has a worse prognosis. Despite Neo-Bioscore has been validated as an independent prognostic model for
breast cancer submitted to NAC, non-pCR carcinoma was not assessed in this setting.
Methods: This is a retrospective trial that included women with localized breast cancer who underwent NAC and
had non-pCR carcinoma in surgical specimen between 01/01/2013 to 12/31/2015 with a three-year follow-up.
Survival analysis was performed by Kaplan-Meier estimator and hazard ratio (HR) set by log-rank test for the primary
and secondary endpoints, respectively Disease-Free Survival (DFS) and Overall Survival (OS). According to Neo-Bioscore,
the proposed prognostic model named Clustered Neo-Bioscore was classified into low (0–3), low-intermediate (4–5),
high-intermediate (6) and high (7) risk. The prognostic accuracy for recurrence risk was assessed by time-dependent
receiver operating characteristic (time-ROC) methodology. Multivariate Cox regression assessed the menopausal status,
histological grade, Ki-67, estrogen receptor, HER2, tumor subtype, pathological and clinical stages. Confidence interval
at 95% (CI95%) and statistical significance at set 2-sided p-value less than 0.05 were adopted.
Results: Among the 310 women enrolled, 267 patients (86.2%) had non-pCR carcinoma presenting size T3/T4 (63.3%),
node-positive axilla (74.9%), stage III (62.9%), Ki-67≥ 20% (71.9%) and non-luminal A (78.3%). Non-pCR carcinoma
presented worse DFS-3y (HR = 3.88, CI95% = 1.18–11.95) but not OS-3y (HR = 2.73, CI95% = 0.66–11.40). Clustered Neo-
Bioscore discerned the recurrence risk for non-pCR carcinoma: low (DFS-3y = 0.86; baseline), low-intermediate (DFS-
3y = 0.70; HR = 2.61), high-intermediate (DFS-3y = 0.13, HR = 14.05), and high (DFS-3y = not achieved; HR = 22.19). The
prognostic accuracy was similar between Clustered Neo-Bioscore and Neo-Bioscore (0.76 vs 0.78, p > 0.05). Triple-
negative subtype (HR = 3.6, CI95% = 1.19–10.92) and pathological stages II (HR = 5.35, CI95% = 1.19–24.01)
and III (HR = 6.56, CI95% = 1.29–33.32) were prognoses for low-intermediate risk, whereas pathological stage III
(HR = 13.0, CI95% = 1.60–106.10) was prognosis for low risk.
Conclusions: Clustered Neo-Bioscore represents a novel prognostic model of non-pCR carcinoma undergoing
NAC with a more simplified and appropriate score pattern in the assessment of prognostic factors.
Keywords: Breast, Carcinoma, Neoadjuvant therapy, Prognosis, Disease-free survival
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: uandersonmed@gmail.com
Division of Gynecological and Mammary Oncology, Woman’s Hospital Dr
José Aristodemo Pinotti (CAISM) of State University of Campinas (UNICAMP),
Rua Alexander Fleming 101, Campinas, São Paulo 13083-083, Brazil
Resende et al. BMC Cancer          (2019) 19:601 
https://doi.org/10.1186/s12885-019-5812-0
Background
Breast cancer is the most common malignant tumor in
women worldwide with about 22% of all new cancers in
2015 [1]. In recent years, new data on the molecular het-
erogeneity of breast carcinoma have led to a greater un-
derstanding of the diversity of prognosis [2].
Neoadjuvant chemotherapy (NAC) is one of the main
therapeutic modalities in the treatment of high-risk
breast cancer [3] due to tumor downstaging with in-
creased rate of conservative breast surgery [4], better
model of clinical research to evaluate the performance
of biomarkers and tumor sensitivity to chemotherapeutic
agents [5], generally using a smaller sample size and
shorter follow-up time [6].
The main prognostic factors of breast cancer are
age, clinical performance, menopausal status, tumor
stage [7], histological type, tumor differentiation, gene
expression signature [8, 9], molecular subtype [10,
11], expression of estrogen (ER) [12, 13] and proges-
terone receptors (PR) [14], HER2 oncoprotein (HER2)
[15] and cellular proliferation index Ki67 (Ki-67) [16–
18]. However, these factors alone have limited prog-
nostic power while combining them into an algorithm
increases the prognostic power [19]. Neo-Bioscore is
currently the leading prognostic model for assessing
the recurrence risk in women with breast cancer
undergoing NAC. It is calculated from the sum of the
scores obtained from the degree of tumor differenti-
ation, ER, HER2, clinical and pathological stages [20–
22]. However, Neo-Bioscore has eight recurrence risk
scores (0 to 7) whose survival curves presented a
non-linear time-to-event distribution among them due
to the non-uniform distance among time-to-event
occurrences [21, 22].
Breast carcinoma undergoing NAC that did not
present a pathological complete response (non-pCR)
has a worse prognosis [23–27] and there is little in-
formation on its independent prognostic factors [28].
Therefore, it would be appropriate to assess a novel
prognostic model that is more simplified to deal
with linear stratification of scores for women with
non-pCR carcinoma. We propose a novel prognostic
model named Clustered Neo-Bioscore from the clus-
tering of similar prognostic scores of Neo-Bioscore
which is composed of four scores - low, low-
intermediate, high-intermediate and high-risk -
whose risk strata are linearly more distanced from
each other as to the time-to-event of tumor recur-
rence in the survival curve. Clustered Neo-Bioscore
and Neo-Bioscore were compared for prognostic ac-
curacy. Independent prognostic factors for non-pCR
carcinoma were analyzed by Cox regression accord-




This is a retrospective cohort that included women with
localized breast carcinoma who underwent NAC
followed by surgery at the Woman’s Hospital Dr. José
Aristodemo Pinotti (CAISM) of the State University of
Campinas (UNICAMP), between 01/01/2013 to 12/31/
2015. It was approved by the Ethics Committee in Re-
search of the Faculty of Medical Sciences (FCM) of UNI-
CAMP. A total of 345 women were selected but 35
patients were excluded due to neoadjuvant hormonal
therapy (25), surgical contraindication (2), clinical co-
morbidities (2), or metastases diagnosed throughout
NAC (6). Therefore, 310 women were enrolled in this
analysis.
Materials
The clinical and biological factors analyzed were meno-
pausal status, tumor size, axilla status, clinical stage,
histologic grade, ER, Ki67, HER2 and molecular subtypes
according to immunohistochemical findings [18, 29–31].
Pathologic analyzes and immunohistochemical assays of
core needle biopsy and surgical specimen were per-
formed in the same institutional laboratory. Menopausal
status was defined as the presence of amenorrhea greater
than 1 year or serum estradiol levels below 10 pg/ml.
The ER expression was classified by Allred scoring into
negative, low (2–6) and high (7–8) [32]. The Ki-67 ex-
pression was subdivided into low (< 20%), intermediate
(20% ≤ Ki67 < 50%) and high (≥ 50%) [33, 34]. Molecular
subtypes were luminal A, luminal B, HER2 and triple-
negative (TN) based on the results of the immunohisto-
chemistry assay [9, 29–32].
NAC protocol
Enrolled women received 4 cycles of doxorubicin 60 mg/
m2 and cyclophosphamide 600 mg/m2 at intervals of 3
weeks followed by 4 cycles of paclitaxel 210 mg/m2 at in-
tervals 3 weeks (4 AC + 4 T) or 12 cycles of paclitaxel 80
mg/m2 weekly (4 AC + 12 T) [35]. About 85% (63/74) of
women with HER2 carcinoma also received trastuzumab
at 4 mg/kg (initial dose) followed by 2 mg/kg weekly for
23 consecutive weeks plus 9 cycles at 6 mg/kg at inter-
vals 3°weeks [36]. Approximately 1% (9/94) of women
with TN carcinoma also received carboplatin AUC = 1.5
weekly associated with paclitaxel [37]. None of the
women showed serious adverse effects that required dis-
continuation of NAC. No one dropped out of NAC due
to loss of follow-up or weak treatment compliance.
There were dose reductions and/or delays for 52 women
by neuropathic (37) and emetic (9) toxicity, surgery an-
ticipation (4) or no clinical response (2). Dose reduction
by only 20% (43) and/or one cycle (4) was the majority
and therefore without influencing the overall efficacy of
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NAC. The period between the last cycle of chemother-
apy and surgery was 20–30 days. Surgical clips were used
to identify the tumor location by mammography in the
surgery. The clinical staging by TNM classification was
performed by clinical examination, mammography, breast
and axillary ultrasound, bone scan computed tomography
of chest and abdominal [38, 39]. Supportive care such as
antiemetic, blood transfusion and antimicrobial therapy
were given according to oncologist’s discretion. The pCR
was defined as the absence of invasive carcinoma in surgi-
cal breast specimen and micro or macrometastases in re-
moved axillary lymph nodes [24, 27, 36–38].
Treatment assessment
The principal outcome was Disease-Free Survival (DFS)
that was defined from the date of diagnosis until the
date of death, locoregional or distant recurrence. The
secondary outcome was Overall Survival (OS) that was
defined from the date of diagnosis until the date of
death. The follow-up time was 37months. The Neo-
Bioscore was calculated from the sum of the scores of
the following data: clinical stage (I/IIA: 0 point, IIB/IIIA:
1 point, IIIB/IIIC: 2 points), pathological stage (0/I: 0
point; IIIB: 1 point, IIIC: 2 points), ER (negative: 1 point;
positive: 0 point), nuclear grade (I/II: 0 point; III: 1
point) and HER2 (negative: 1 point; positive: 0 point)
[19–22]. The Clustered Neo-Bioscore was calculated
from Neo-Bioscore by grouping prognostic scores simi-
lar into each other to obtain four very different prognos-
tic categories: low (0, 1, 2 or 3), low-intermediate (4 or
5), high-intermediate (6) and high (7). This configuration
of categories presented greater homogeneity within them
and heterogeneity among them leading to a greater
time-to-event distance for tumor recurrence among the
categories.
Statistical analysis
Statistical analysis was performed by SPSS 22.0 software
(version 22; SPSS Inc). Categorical variables were ana-
lyzed with Pearson’s chi-square test and Kendal’s Tau for
multinomial regression according to pathological re-
sponse and Neo-Bioscore. The Kaplan-Meier estimator
was used to obtain the time-to-event for recurrence
tumor of pCR and non-pCR carcinomas according to
Neo-Bioscore and Clustered Neo-Bioscore, survival
curves for a 3-year follow-up and the hazard ratio (HR)
between pCR and non-pCR carcinomas for DFS-3y and
OS-3y. The log-rank test was used to compare the prog-
nosis among the risk scores of the pathological stage (I,
II and III), Neo-Bioscore (0 to 7) and Clustered Neo-
Bioscore (low, low-intermediate, high-intermediate and
high). The mean time to first relapse (mTFR) and the re-
spective HR among the risk categories of Clustered Neo-
Bioscore were calculated by Kaplan-Meier, while the
statistical significance was defined by the log-rank test.
The multivariate analysis by Cox proportional hazards
regression was performed to define the independent
prognostic factors of non-pCR carcinoma according to
Neo-Bioscore, low and low-intermediate Clustered-Neo-
Bioscore. The Cox regression for intermediate-high and
high risk was not performed because of the limited
number of patients in these groups [40, 41]. The prog-
nostic accuracy for recurrence risk among the patho-
logical stage, Neo-Bioscore and Clustered Neo-Bioscore
was assessed from the area under the curve (AUC) by
time-dependent receiver operating characteristic (time-
ROC) methodology. The confidence interval at 95%
(CI95%) was adopted and statistical significance was at
set 2-sided p-value less than 0.05 (p < 0.05) [42].
Results
Patient characteristics
Women with high-risk breast cancer prevailed with size
T3/T4 (64%), stage III (62%), positive axilla (74%), Ki-
67 ≥ 20% (74%) and non-Luminal A (81%). The pCR car-
cinoma was about 13.8% (43/310) of the total with histo-
logical grade III (62.8%), negative ER (74.4%), Ki-67 ≥
20% (88.4%), HER2 and TN (93%) subtypes, T3/T4 size
(69.8%), N1 axilla (48.8%) and stage III (58.1%). Other-
wise, the non-pCR carcinoma presented similar clinical
characteristics to pCR carcinoma with size T3/T4
(63.3%), axilla N1 (43.8%) and stage III (62.9%) but dif-
ferent biological factors with histological grade I/II
(53.9%), ER Allred 7–8 (49.4%), Ki-67 < 50% (71.5%) and
Luminal B (30.3%) (Table 1).
Most of the carcinomas had Neo-Bioscore ≤5 (91.0%;
282/310) with histological grade I/II (56.7%; 160/282),
positive ER (61.0%; 172/282), Ki-67 < 50% (70.2%; 198/
282), negative HER2 (74.8%; 211/282), non-TN subtype
(72.3%; 204/282), size T3/T4 (60.6%; 171/282), node-
positive axilla (71.2%; 201/282) and stage III (62.1%; 175/
282). Carcinomas classified as Neo-Bioscore = 0–3 (48.4%;
150/310) prevailed in premenopausal status (55.3; 83/150),
histological grade I/II (76.7%; 115/150), ER Allred 7–8
(56.0%; 84/150), Ki-67 < 50% (64.0%; 114/150), negative
HER2 (66.7%; 100/150), non-TN subtype (80.7%; 121/
150), size T1/T2 (58.7%; 88/150), node-positive axilla
(59.3%; 89/150) and stage I/II (60.7%; 91/150). Carcinomas
classified as Neo-Bioscore = 4–5 (42.6%; 132/310) pre-
vailed in postmenopausal status (58.3%; 77/132), histo-
logical grade III (65.9%; 87/132), negative ER (50.8%; 67/
132), Ki-67 ≥ 20% (75.8%; 100/132), negative HER2
(84.1%; 111/132), non-luminal A subtype (80.3%; 106/
132), size T3/T4 (82.6%; 109/132), positive axilla (84.8%;
112/132) and stage III (80.3%; 106/132). Otherwise, car-
cinomas classified as Neo-Bioscore = 6–7 (9.0%; 28/310)
prevailed in postmenopausal status (64.3%; 18/28), histo-
logical grade III (100%; 28/28), negative ER (75.0%; 21/28),
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Table 1 Clinical and biological characteristics of breast carcinoma according to pathological response and Neo-Bioscore
Characteristics n Pathological response Neo-Bioscore
pCRa non-pCR 0 1 2 3 4 5 6 7
310 (100%) 43 (13.8%) 267 (86.2%) 1 (0.3%) 18 (5.8%) 47 (15.2%) 84 (27.1%) 83 (26.8%) 49 (15.8%) 23 (7.4%) 5 (1.6%)
Menopausal status
Premenopausal 148 (48%) 21 (48.8%) 127 (47.6%) 0 (0%) 10 (55.6%) 31 (66%) 42 (50.0%) 33 (39.8%) 22 (44.9%) 8 (34.8%) 2 (40%)
Postmenopausal 162 (52%) 22 (51.1%) 140 (52.4%) 1 (100%) 8 (44.4%) 16 (34%) 42 (50.0%) 50 (60.2%) 27 (55.1%) 15 (65.2%) 3 (60%)
Histological grade
I/II 160 (52%) 16 (37.2%) 144 (53.9%) 1 (100%) 17 (94.4%) 36 (76.6%) 61 (72.6%) 34 (41.0%) 11 (22.4%) 0 (0%) 0 (0%)
III 150 (48%) 27 (62.8%) 123 (46.1%) 0 (0%) 1 (5.6%) 11 (23.4%) 23 (27.4%) 49 (59.0%) 38 (77.6%) 23 (100%) 5 (100%)
Estrogen receptor
Negative 131 (42%) 32 (74.4%) 99 (37.1%) 0 (0%) 2 (11.1%) 10 (21.3%) 31 (36.9%) 43 (51.8%) 24 (49%) 16 (69.6%) 5 (100%)
Allred 2–6 (< 70%) 40 (13%) 4 (9.3%) 36 (13.5%) 1 (100%) 4 (22.2%) 7 (14.9%) 11 (13.1%) 8 (9.6%) 8 (16.3%) 1 (4.3%) 0 (0%)
Allred 7–8 (≥70%) 139 (45%) 7 (16.3%) 132 (49.4%) 0 (0%) 12 (66.7%) 30 (63.8%) 42 (50.0%) 32 (38.6%) 17 (34.7%) 6 (26.1%) 0 (0%)
Ki-67
< 20% 80 (26%) 5 (11.6%) 75 (28.1%) 0 (0%) 6 (33.3%) 13 (27.7%) 27 (32.1%) 20 (24.1%) 12 (24.5%) 2 (8.7%) 0 (0%)
20–50% 134 (43%) 18 (41.9%) 116 (43.4%) 0 (0%) 8 (44.5%) 22 (46.8%) 38 (45.2%) 35 (42.2%) 17 (34.7%) 12 (52.2%) 2 (40%)
≥ 50% 96 (31%) 20 (46.5%) 76 (28.5%) 1 (100%) 4 (22.2%) 12 (25.5%) 19 (22.7%) 28 (33.7%) 20 (40.8%) 9 (39.1%) 3 (60%)
HER2
Negative 236 (76%) 24 (55.8%) 212 (79.4%) 0 (0%) 10 (55.6%) 28 (59.6%) 62 (73.8%) 66 (79.5%) 45 (91.8%) 20 (87.0%) 5 (100%)
Positive 74 (24%) 19 (44.2%) 55 (20.6%) 1 (100%) 8 (44.4%) 19 (40.4%) 22 (26.2%) 17 (20.5%) 4 (8.2%) 3 (13.0%) 0 (0%)
Subtype
A 59 (19%) 1 (2.3%) 58 (21.7%) 0 (0%) 5 (27.8%) 9 (19.1%) 18 (21.4%) 16 (19.3%) 10 (20.4%) 1 (4.3%) 0 (0%)
B 83 (27%) 2 (4.7%) 81 (30.3%) 0 (0%) 5 (27.8%) 14 (29.8%) 20 (23.8%) 20 (24.1%) 16 (32.7%) 8 (34.8%) 0 (0%)
HER2 74 (24%) 19 (44.2%) 55 (20.6%) 1 (100%) 8 (40.4%) 19 (40.5%) 22 (26.2%) 17 (20.5%) 4 (8.2%) 3 (13%) 0 (0%)
TN 94 (30%) 21 (48.8%) 73 (27.4%) 0 (0%) 0 (0%) 5 (10.6%) 24 (28.6%) 30 (36.1%) 19 (38.7%) 11 (47.9%) 5 (100%)
Size
T1/T2 111 (36%) 13 (30.2%) 98 (36.7%) 1 (100%) 17 (94.4%) 28 (59.6%) 42 (50.0%) 21 (25.3%) 2 (4.1%) 0 (0%) 0 (0%)
T3/T4 199 (64%) 30 (69.8%) 169 (63.3%) 0 (0%) 1 (5.6%) 19 (40.4%) 42 (50.0%) 62 (74.7%) 47 (95.9%) 23 (100%) 5 (100%)
Axilla
Negative 82 (26%) 15 (34.9%) 67 (25.1%) 1 (100%) 12 (66.7%) 24 (51.1%) 24 (28.6%) 11 (13.3%) 9 (18.4%) 1 (4.3%) 0 (0%)
N1 138 (45%) 21 (48.8%) 117 (43.8%) 0 (0%) 5 (27.8%) 19 (40.4%) 37 (44.0%) 45 (54.2%) 22 (44.9%) 8 (34.8%) 2 (40%)
N2/N3 90 (29%) 7 (16.3%) 83 (31.1%) 0 (0%) 1 (5.6%) 4 (8.5%) 23 (27.4%) 27 (32.5%) 18 (36.7%) 14 (60.9%) 3 (60%)
Stage
I/II 117 (38%) 18 (41.9%) 99 (37.1%) 1 (100%) 16 (88.9%) 32 (68.1%) 42 (50.0%) 21 (25.3%) 5 (10.2%) 0 (0%) 0 (0%)
III 193 (62%) 25 (58.1%) 168 (62.9%) 0 (0%) 2 (11.1%) 15 (31.9%) 42 (50.0%) 62 (74.7%) 44 (89.8%) 23 (100%) 5 (100%)











Ki-67 ≥ 20% (92.9%; 26/28), negative HER2 (89.3%; 25/28),
TN subtype (57.1%; 16/28), size T3/T4 (100%; 28/28),
positive axilla (96.4%; 27/28) and stage III (100%; 28/28)
(Table 1).
Survival analysis
The women enrolled in this study presented median
time from first recurrence (mTFR) equal to 1274 d
(CI95%: 1219–1329), DFS-3y = 0.75 (CI95%: 0.72–0.78),
median overall survival (mOS) of 1405 d (CI95%: 1360–
1449) and OS-3y = 0.81 (CI95%: 0.79–0.84). The pCR
carcinoma occurred in 43 women (13.8%) with mTFR =
1432 d (CI95%: 1339–1525) and DFS-3y = 0.92 (CI95%:
0.88–0.96). Otherwise, 267 women had non-pCR carcin-
oma (86.7%) with mTFR = 1244 d (CI95%: 1182–1305)
and DFS-3y = 0.69 (CI95%: 0.65–0.73) (Table 2). At 3-
years non-pCR carcinoma showed a greater recurrence
risk than pCR carcinoma with HR = 3.75 (CI95%: 1.18–
11.95) but not the death risk with HR = 2.73 (CI95%:
0.66–11.35) (Fig. 1).
Considering the group of 43 pCR carcinomas, 65.1% of
the total (28/43) was classified as Clustered Neo-Bioscore
of low risk (Neo-Bioscore 0–3) with DFS-3y = 0.93 (0.87–
0.99) and 34.9% (15/43) was of low-intermediate risk
(Neo-Bioscore 4–5) with DFS-3y = 0.92 (0.86–0.98) (Table
2). For group of 267 non-pCR carcinomas, 45.7% (122/
267) was of low risk with DFS-3y = 0.86 (CI95%: 0.82–
0.90), 43.8% (117/267) was of low-intermediate risk with
DFS-3y = 0.70 (CI95%: 0.65–0.75), 8.6% (23/267) was
of high-intermediate risk (Neo-Bioscore 6) with DFS-
3y = 0.13 (CI95%: 0.05–0.21) and 1.9% (5/267) was of
high risk (Neo-Bioscore 7) with DFS-3y = 0 (mTFR =
475 d) (Table 2).
The subdivision of the scores for pathological
staging (I, II and III), Neo-Bioscore (0 to 7) and
Clustered Neo-Bioscore (low, low-intermediate, high-
intermediate and high) presented statistical signifi-
cance in relation to the risk of tumor recurrence for
non-pCR carcinoma (p < 0.01) (Fig. 2). The prognos-
tic accuracy was assessed by the time-ROC model
(p > 0.05) between Neo-Bioscore (0.78, CI95%: 0.71–
0.84) and Clustered Neo-Bioscore (0.76; CI95%: 0.69–
0.83). Otherwise, these markers presented greater
accuracy (p < 0.01) than the pathological stage (0.69;
CI95%: 0.63–0.76) (Fig. 3).
The Clustered Neo-Bioscore subgroups of non-pCR
carcinoma had remarkably different recurrence risks
with statistical significance among them (p < 0.01). Con-
sidering the low risk as reference (mTFR = 1388 d), the
low-intermediate risk presented mTFR = 1247 d (HR =
2.61, CI95%: 1.33–5.11), the high-intermediate risk had
mTFR = 618 d (HR = 14.05, CI95%: 6.78–29.11) and the
high risk showed mTFR = 433 d (HR = 22.19, CI95%:
7.70–63.92) (Table 3).
Multivariate analysis
Considering Neo-Bioscore, the multivariate Cox regres-
sion analysis for tumor recurrence of non-pCR carcin-
oma showed that only the pathological stage was an
independent prognostic factor. Taking the pathological
Table 2 Recurrence risk according to pathological response, Neo-Bioscore and Clustered Neo-Bioscore
Neo-Bioscore All patients pCRc non-pCR
n = 310 DFS-3y (CI95%)a n = 43 DFS-3y (CI95%) n = 267 DFS-3y (CI95%)
0 1 (0.3%) 1.00 0 1.00 1 (0.4%) 1.00
1 18 (5.8%) 1.00 5 (11.6%) 1.00 13 (4.9%) 1.00
2 47 (15.2%) 0.88 (0.81–0.95) 12 (27.9%) 0.89 (0.79–0.99) 35 (13.1%) 0.86 (0.75–0.97)
3 84 (27.1%) 0.83 (0.78–0.88) 11 (25.6%) 0.91 (0.82–1.00) 73 (27.3%) 0.82 (0.76–0.88)
4 83 (26.8%) 0.78 (0.73–0.83) 14 (32.6%) 0.93 (0.87–1.00) 69 (25.8%) 0.74 (0.68–0.80)
5 49 (15.8%) 0.66 (0.57–0.75) 1 (2.3%) 1.00 48 (18.0%) 0.62 (0.51–0.73)
6 23 (7.4%) 0.13 (0.05–0.21) 0 – 23 (8.6%) 0.13 (0.05–0.21)
7 5 (1.6%) 0 (mTFR = 475 d)b 0 – 5 (1.9%) 0 (mTFR = 475 d)
Total 0.73 (0.70–0.76) Total 0.92 (0.88–0.96) Total 0.69 (0.65–0.73)
Clustered Neo-Bioscore All patients pCR non-pCR
n = 310 DFS-3y (CI95%) n = 43 DFS-3y (CI95%) n = 267 DFS-3y (CI95%)
0–3 150 0.87 (0.83–0.91) 28 (65.1%) 0.93 (0.87–0.99) 122 (45.7%) 0.86 (0.82–0.90)
4–5 132 0.73 (0.68–0.78) 15 (34.9%) 0.92 (0.86–0.98) 117 (43.8%) 0.70 (0.65–0.75)
6 23 (7.4%) 0.13 (0.05–0.21) 0 – 23 (8.6%) 0.13 (0.05–0.21)
7 5 (1.6%) 0 (mTFR = 475 d) 0 – 5 (1.9%) 0 (mTFR = 475 d)
aDFS-3y 3-year disease-free survival rate
bmTFR median time to the first recurrence
cpCR pathological complete response
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stage I as the reference, the pathological stage II had
HR = 8.12 (CI95%: 2.40–27.53) and the pathological
stage III had HR = 16.24 (CI95%: 4.71–55.95). Other-
wise, the Clustered Neo-Bioscore presented distinct
results with greater discrimination of independent
pathological factors compared to Neo-Bioscore. For
the low risk, the pathological stage III was the only
independent prognostic factor (HR = 13.0; CI95%: 1.6–
106.1). For the low-intermediate risk, TN subtype
(HR = 3.60; CI95%: 1.19–10.92) and pathological
stages II (HR = 5.35; CI95%: 1.19–24.01) and III (HR =
6.56; CI95%: 1.29–33.32) were independent prognos-
tic factors (Table 4 and Fig. 4).
Discussion
The Clustered Neo-Bioscore was a prognostic model of
equivalent accuracy to Neo-Bioscore in women with
non-pCR carcinoma but presented a more simplified
categorization of scores, better differentiation among
their prognostic scores and greater ability to identify in-
dependent prognostic factors.
Clustered Neo-Bioscore presented a prognostic accur-
acy in the risk of tumor recurrence with no statistically
significant difference in relation to Neo-Bioscore for
non-pCR breast carcinoma according to the ROC-time
model. Otherwise, both models had greater prognostic
accuracy compared than pathological stage [19, 20].
Fig. 1 Disease-Free Survival (a) and Overall Survival (b) according to pathological response
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Neo-Bioscore previously showed greater prognostic ac-
curacy than pathological staging but this analysis did not
exclusively involve non-pCR breast carcinoma [21, 22].
Therefore, the clustering of risk scores of Neo-Bioscore
based on prognostic similarity did not bring about a loss
of prognostic power to Clustered Neo-Bioscore. On the
other hand, Clustered Neo-Bioscore has a simpler
pattern with only four risk scores to allocate and define
the prognosis of women undergoing NAC who have a
worse prognosis because they have residual carcinoma
in surgical specimen.
Most published clinical trials have evaluated the
prognostic factors of women undergoing NAC with
pCR carcinoma, therefore, a better oncological prog-
nosis [25–27]. Otherwise, this trial turned to a better
understanding of the prognostic factors for women
with non-pCR carcinoma due to their worse survival.
The main objective of this trial was to assess the
prognosis of women with residual carcinoma after
NAC. Previous data show that usually 80–90% of the
women submitted to NAC present residual carcinoma
in the surgical specimen. Unlike most of the trials
that evaluated pCR carcinoma this trial focused on
the prognostic factors of women who did not reach
pCR [19–22].
Analysis of survival results by Mittendorf ’s pivotal
trial [21] showed that the curves and survival at 3-
year for 10-year follow-up were very similar to the re-
sults obtained in our trial. About 13.8% of the women
had non-pCR carcinoma that showed a 3.88-fold
greater risk of tumor recurrence than those with pCR
carcinoma at 3-year follow-up (p = 0.025). However,
there was no statistically significant difference for
overall survival (p = 0.17) due to the shorter follow-up
time since the survival curves between pCR and non-
pCR carcinomas progressively move away from each
other over time [23–26].
The subdivision of Clustered Neo-Bioscore into four
risk scores was based on similar survival of Neo-
Bioscore scores so that these new categories were inde-
pendent and heterogeneous on prognosis. That is, the
elevation of prognostic risk to tumor recurrence in-
creased more linearly between the scores. Figure 2
showed that the survival curves for the risk scores of
Clustered Neo-Bioscore were markedly distanced from
each other, providing an adequate distinction of the
prognostic value for tumor recurrence among the low,
intermediate, high-intermediate, and high risk (p < 0.01)
. According to Table 3, non-pCR breast carcinoma clas-
sified as high-intermediate or high risk by Clustered-
Neo-Bioscore, although only 9% of the total, presented a
risk of recurrence much higher than those classified as
low or low-intermediate, which account for about 91%
of the total. Taking the low risk as a reference, high-
intermediate and high risks had respectively 14-fold and
22-fold greater risk of tumor recurrence. Otherwise,
women classified as low-intermediate risk had about 2.6-
fold greater recurrence risk. Table 2 also showed that
the distribution of risk scores in Clustered Neo-Bioscore
at 3-years follow-up (DFS-3y) was more suitably hetero-
geneous to classify and distinguish women with non-
Fig. 2 Disease-Free Survival for non-pCR carcinoma according to
pathological stage (a), Neo-Bioscore (b) and Clustered Neo-Bioscore (c)
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pCR carcinoma. The confidence intervals of the DFS-3y
values for the risk scores in Clustered Neo-Bioscore do
not overlap unlike the Neo-Bioscore scores of 0 to 5.
Considering the Neo-Bioscore model, Cox regression
showed that only the pathological stage was an inde-
pendent prognostic factor for tumor recurrence in
women with non-pCR breast carcinoma after NAC. The
results showed that stages II and III were associated with
8-fold and 16-fold greater recurrence risk compared to
the stage I. On the other hand, Neo-Bioscore did not
identify any biological marker as a prognostic risk, con-
trary to what has been observed in some trials in which
the biological nature of the tumor plays an important
role in the prognosis [23, 25–28, 43]. Regarding Clus-
tered Neo-Bioscore, Cox regression can only be per-
formed for non-pCR carcinomas of low and low-
intermediate risks which accounted for about 91% of
total women. Non-pCR carcinomas of high-intermediate
and high risks enrolled only 23 and 5 patients,
respectively, which made it impossible to perform the
multivariate analysis.
Clustered Neo-Bioscore presented Cox regression re-
sults different from Neo-Bioscore with better power in
discriminating independent prognostic factors. For non-
pCR carcinoma of low risk, only pathologic stage III was
an independent prognostic factor with 13-fold greater re-
currence risk compared to the stage I. That is, only bulky
tumor after NAC (greater than 5 cm and/or N2/N3) had
worse prognosis in low-risk non-pCR carcinoma. Other-
wise, non-pCR carcinoma of low-intermediate risk
showed that TN subtype (3.60-fold) and pathological
stages II (5.35-fold) and III (6.56-fold) had a greater risk of
tumor recurrence. Some clinical trials have shown the
prognostic risk of residual tumor after NAC but there is
less information on the prognostic correlation be-
tween residual tumor volume and the biological fac-
tors of carcinoma as shown by the low-intermediate
risk [24, 28, 43]. TN carcinoma is usually highly che-
mosensitivity and has high potential to reach pCR.
However, results for non-pCR carcinoma of low-
intermediate risk showed that TN subtype has a
worse prognosis when it is associated with residual
tumor after NAC (stages II and III) [16–22, 27, 43].
The results provided by Clustered Neo-Bioscore indi-
cate the need to better identify prognostic factors associ-
ated with non-PCR breast cancer to evaluate new
strategies related to NAC such as the number of chemo-
therapy cycles to be used, drug combination, assessment
Fig. 3 Prognostic accuracy by time-ROC method for non-pCR carcinoma according to pathological stage, Neo-Bioscore and Clustered Neo-
Bioscore. AUC – Area Under Curve. AUC Clustered Neo-Bioscore = 0.76 (CI95%: 0.69–0.83). AUC Neo-Bioscore = 0.78 (CI95%: 0.71–0.84). AUC
Pathological stage = 0.69 (CI95%: 0.63–0.76)
Table 3 Recurrence risk of non-pCR carcinoma according to
Clustered Neo-Bioscore
Clustered Neo-Bioscore mTFRa (days) p HRb (CI95%)
Low 1388 Reference
Low-intermediate 1247 < 0.01 2.61 (1.33–5.11)
High-intermediate 618 < 0.01 14.05 (6.78–29.11)
High 433 < 0.01 22.19 (7.70–63.92)
amTFR median time to the first recurrence
bHR Hazard ratio at 3 years
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of tumor downstaging, identification of new biomarkers
of tumor resistance or new protocols to complement the
NAC in order to reduce the risk of tumor recurrence.
The breast carcinomas analyzed in this clinical trial pre-
sented high-risk clinical and biological characteristics
predominating size T3/T4 size, positive axilla, clinical
stage III, histological grade III, non-luminal carcinoma
A, negative ER and Ki-67 ≥ 20%.
Conclusions
In summary, Clustered Neo-Bioscore demonstrated po-
tential as a better marker for prognostic analysis of non-
pCR carcinoma undergoing NAC, since it had a prog-
nostic accuracy equivalent to Neo-Bioscore, but pre-
sented a more simplified format in the subdivision of
risk scores, a better model to discriminate the prognosis
among the risk scores due to the greater prognostic dif-
ferentiation and a better pattern in the assessment of in-
dependent prognostic factors in women classified as low
and low-intermediate risks.
This is a retrospective clinical trial with limitations
inherent to bias control and confounding factors, but
we believe that it makes an important scientific con-
tribution to understanding the prognostic factors of
Table 4 Recurrence risk by Cox regression analysis of non-pCR carcinoma according to Neo-Bioscore and Clustered Neo-Bioscore of
low and low-intermediate risks




HRa (CI95%) HR (CI95%) HR (CI95%)
Menopausal status
Premenopausal Reference Reference Reference
Postmenopausal 0.75 (0.45–1.27) 0.73 (0.19–2.77) 0.91 (0.41–2.03)
Histological grade
I/II Reference Reference Reference
III 1.33 (0.77–2.30) 2.05 (0.32–13.27) 0.77 (0.34–1.74)
Ki-67
0–20% Reference Reference Reference
20–50% 2.29 (0.68–7.73) 0.76 (0.12–4.79) 2.39 (0.29–19.89)
≥ 50% 3.39 (0.99–11.58) 4.81 (0.41–56.41) 3.37 (0.41–27.57)
Estrogen receptor
Allred 7–8 (≥70%) Reference Reference Reference
Allred 2–6 (< 70%) 1.54 (0.49–4.88) 2.17 (0.23–20.02) 0.53 (0.15–1.82)
Negative 1.35 (0.44–4.15) 1.33 (0.11–16.67) 1.39 (0.16–12.50)
HER2
Negative Reference Reference Reference
Positive 0.58 (0.15–2.28) 1.45 (0.34–6.17) 0.83 (0.20–3.50)
Tumor subtype
A Reference Reference Reference
B 0.50 (0.12–2.12) 0.53 (0.09–3.20) 1.10 (0.49–2.50)
HER2 0.58 (0.15–2.28) 1.45 (0.34–6.17) 0.83 (0.20–3.50)
TN 1.90 (0.49–7.30) 8.92 (0.94–84.93) 3.60 (1.19–10.92)
Clinical stage
I/II Reference Reference Reference
III 1.81 (0.88–3.75) 2.70 (0.60–12.21) 1.00 (0.38–2.66)
Pathological stage
I Reference Reference Reference
II 8.12 (2.40–27.53) 4.17 (0.47–37.33) 5.35 (1.19–24.01)
III 16.24 (4.71–55.95) 13.00 (1.60–106.10) 6.56 (1.29–33.32)
aHR Hazard ratio at 3 years
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non-pCR breast carcinoma. External validation trials
should be performed to evaluate the generality of the
results obtained.
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Additional file 1: Datasets supporting the study findings. (XLSX 122 kb)
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